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Calmodulin-dependent protein kinase kinase-β activates AMPK without
forming a stable complex: synergistic effects of Ca2+ and AMP
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Activation of AMPK (AMP-activated protein kinase) by
phosphorylation at Thr
172 is catalysed by at least two distinct
upstream kinases, i.e. the tumour suppressor LKB1, and
CaMKKβ (Ca
2+/calmodulin-dependent protein kinase kinase-β).
The sequence around Thr
172 is highly conserved between the two
catalytic subunit isoforms of AMPK and the 12 AMPK-related
kinases, and LKB1 has been shown to act upstream of all of them.
In the present paper we report that none of the AMPK-related
kinases tested could be phosphorylated or activated in intact cells
or cell-free assays by CaMKKβ, although we did observe a slow
phosphorylation and activation of BRSK1 (brain-speciﬁc kinase
1) by CaMKKα. Despite recent reports, we could not ﬁnd any
evidence that the α and/or β subunits of AMPK formed a stable
complex with CaMKKβ. We also showed that increasing AMP
concentrations in HeLa cells (which lack LKB1) had no effect
on basal AMPK phosphorylation, but enhanced the ability of
agents that increase intracellular Ca
2+ to activate AMPK. This is
consistent with the effect of AMP on phosphorylation of Thr
172
being due to inhibition of dephosphorylation, and conﬁrms that
the effect of AMP is independent of the upstream kinase utilized.
Key words: AMP-activated protein kinase (AMPK), AMP-
activated protein kinase-related kinase (ARK), Ca
2+/calmodulin-
dependent protein kinase (CaMK), Ca
2+/calmodulin-dependent
protein kinase kinase (CaMKK).
INTRODUCTION
AMPK (AMP-activated protein kinase) is an energy-sensing
system involved in regulating energy balance at both the
cellular and the whole-body levels [1,2]. The kinase occurs as
heterotrimeric complexes composed of a catalytic α subunit
and regulatory β and γ subunits, with each subunit existing
in mammals as isoforms encoded by multiple genes (α1, α2;
β1, β2; γ1, γ2, γ3). Metabolic stresses that inhibit ATP syn-
thesis (e.g. hypoxia, hypoglycaemia) or that stimulate ATP
consumption (e.g. muscle contraction) cause an increase in the
cellular ADP/ATP ratio, which is ampliﬁed by adenylate kinase
into an even larger increase in the AMP/ATP ratio. AMP and
ATP bind antagonistically to two sites formed by the four tandem
CBS (cystathionine β-synthase) motifs on the γ subunit [3,4].
The kinase is only active after phosphorylation of a critical
threonine residue within the activation loop of the kinase domain
(Thr
172 in rat α1/α2) by upstream kinases. The major upstream
kinase in most cells was identiﬁed to be a complex between the
tumour suppressor LKB1 and two accessory subunits, STRAD
(Ste20-related adaptor) and MO25 (mouse protein 25) [5,6].
LKB1 appears to be constitutively active [7,8] and may therefore
phosphorylate AMPK continually, but under basal conditions
the phosphate appears to be immediately removed by protein
phosphatases.However,bindingofAMPtotheAMPKγ subunits
inhibits dephosphorylation of Thr
172, an effect that is antagonized
by high concentrations of ATP [9–11]. In addition, binding of
AMP (but not ATP) triggers a further allosteric activation of the
phosphorylated kinase by up to 10-fold, with the combination
of these two effects producing >1000-fold activation [11]. Both
stimulatoryeffectsappeartooccurbecauseAMPbindingrelieves
the inhibitory effects of an auto-inhibitory domain on the α
subunit, which binds to the kinase domain on the opposite side to
the substrate-binding site [12]. This represents a sensitive switch
mechanism that produces a large activation of AMPK in response
to a small increase in the cellular AMP/ATP ratio.
Some human tumour cells (e.g. HeLa cells) do not express
LKB1, but AMPK can still be phosphorylated at Thr
172 and
activated in such cells using Ca
2+ ionophores. This led to the
discoverythattheCaMKKs[CaMK(Ca
2+/calmodulin-dependent
protein kinase) kinases], especially CaMKKβ, could act as
alternative upstream kinases that can phosphorylate Thr
172 on
AMPK [13–15]. CaMKKα and CaMKKβ [16] were originally
discovered as CaMKs that acted upstream of CaMKI and
CaMKIV. The Ca
2+→CaMKK→AMPK pathway is triggered by
a rise in cytosolic Ca
2+ without any requirement for an increase
in AMP, and is responsible for AMPK activation in response to
K
+-induced depolarization in neurons [13], muscarinic activation
in neuroblastoma cells [17], thrombin activation of endothelial
cells [18], treatment of smooth muscle cells with vasoconstrictors
[19] and stimulation of antigen receptors in T-cells [20].
The sequence around Thr
172 on the AMPK α subunits is
highly conserved (see Figure 1) in the kinase domain sequences
of kinases [termed ARKs (AMPK-related kinases)], that lie
on the same branch of the human kinome [21]. By studying
phosphorylation in cell-free assays and in cells lacking LKB1,
including LKB1
−/− mouse embryo ﬁbroblasts and HeLa cells,
it was shown that at least 12 of these were also dependent
on LKB1 for basal phosphorylation of the threonine residue
equivalent to Thr
172, and hence for basal activity. These
include the brain-speciﬁc kinases BRSK1 and BRSK2 (also
known as SAD-B and SAD-A), SIK (salt-inducible kinase) 1,
Abbreviations used: ACC, acetyl-CoA carboxylase; AICAR, 5-amino-4-imidazolecarboxamide riboside; AMPK, AMP-activated protein kinase; ARK,
AMPK-related kinase; BRSK, brain-speciﬁc kinase; CaMK, Ca2+/calmodulin-dependent protein kinase; CaMKK, Ca2+/calmodulin-dependent protein
kinase kinase; FBS, foetal bovine serum; GFP, green ﬂuorescent protein; GST, glutathione transferase; HEK, human embryonic kidney; MARK, microtubule
afﬁnity-regulating kinase; MO25, mouse protein 25; NUAK, SNF1 (sucrose-non-fermenting kinase-1)-like kinase; SIK, salt-inducible kinase; STRAD, Ste20-
related adaptor; TBS, Tris-buffered saline; UBA, ubiquitin-associated.
1 To whom correspondence should be addressed (email d.g.hardie@dundee.ac.uk).
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SIK2 and SIK3 (also known as SIK, QIK and QSK respectively),
NUAK [SNF1 (sucrose-non-fermenting kinase-1)-like kinase]
1 and NUAK2 (also known as ARK5 and SNARK), MARK
(microtubule afﬁnity-regulating kinase) 1, MARK2, MARK3
and MARK4, and the testis-speciﬁc kinase SNRK (SNF1-related
kinase) [7,22].
In the present study we have addressed three questions
regarding the regulation of AMPK and the ARKs by CaMKKs.
First, it had not been established whether the ARKs are substrates
for CaMKKs, as is AMPK itself. Secondly, it has recently been
claimed that CaMKKβ can form a complex with the α and
β subunits of AMPK in the absence of a γ subunit [23], a
hypothesis that we wished to conﬁrm. Thirdly, if the effect of
AMP on phosphorylation of Thr
172 on AMPK is due to inhibition
of dephosphorylation we were puzzled as to why, in cells such as
HeLa cells that express CaMKKβ but lack LKB1, AMPK is not
activated by treatments that increase intracellular AMP [5].
EXPERIMENTAL
Materials and proteins
STO-609 was from Tocris Bioscience and calmodulin was
from CN Biosciences. A23187, phenformin and 2-deoxyglucose
were from Sigma. Zeocin and blasticidin were from
Invitrogen. Expression and puriﬁcation of GST (glutathione
transferase)–AMPK-α1, GST–BRSK1, GST–BRSK2, GST–
LKB1:STRAD:MO25 and GST–CaMKKβ were as described
previously [24]. For GST–CaMKKα, a pGEX plasmid encoding
CaMKKα (residues 1–505) was used to transform Escherichia
coli[BL21(DE3)pLys],whichweregrowninLB(Luria–Bertani)
ampicillin at 37◦C until the A600 was 0.4–0.6. Expression was
induced with 50 μM IPTG (isopropyl β-D-thiogalactoside) and
cells harvested after 18 h at 15◦C. The harvested cells were
lysed and GST–CaMKKα afﬁnity-puriﬁed using glutathione–
Sepharose chromatography.
Plasmids
TheGFP(greenﬂuorescentprotein)–AMPK-α1,–AMPK-β1and
–AMPK-γ1plasmidswereasdescribedpreviously[25].Tomake
FLAG-tagged CaMKKβ, a pGEX construct encoding human
CaMKKβ was digested with BamHI and XhoI, and the insert
cloned into the vector pCMV-Tag2B using standard methods.
Antibodies
The antibody against the phosphorylated form of Thr
172 on
the AMPK α subunits was from Cell Signaling Technology.
Antibodies against actin and the FLAG epitope, and sheep
immunoglobulin were from Sigma, antibodies against GFP were
from Roche, antibodies against MARK3 (C-TAK1) were from
Millipore, and antibodies against AMPK-γ1 were from Abcam.
Antibodies against AMPK-α1a n d- α2 [26], LKB1 (N-terminal
dephospho-Ser
31 [24]), CaMKKβ [13], AMPK-pan β [25], GST
[27], and SIK1, SIK2, SIK3, NUAK2, MARK1 and MARK4 [7]
were as described previously.
Cell culture
HEK (human embryonic kidney)-293 cells and the HeLa cells
used in Figures 6 and 7 were cultured in DMEM (Dulbecco’s
modiﬁed Eagle’s medium) containing 10% (v/v) FBS (foetal
bovineserum),100i.u./mlpenicillinand100 μg/mlstreptomycin.
HeLa cells stably expressing wild-type LKB1 and derived from
T-REx
TM HeLa cells (Invitrogen) were as previously described
[28]. The parental T-REx
TM line was used in all experiments
involving HeLa cells except Figures 6 and 7, and was cultured in
Eagle’s minimal essential medium, 10% (v/v) FBS and 5 μg/ml
blasticidin,butwithouttetracycline.CellsstablyexpressingLKB1
weregrowninthismediumwiththeadditionof100 μg/mlzeocin.
The parental cell line was transfected with 10 μg (per 100 mm
diameter dish) of FLAG–CaMKKβ using the polyethylenimine
method [29]. Cells were transfected with combinations (3 μg
each) of GFP–AMPK-α1, β1, γ1 and FLAG–CaMKKβ as
indicated in the text using the polyethylenimine method [29].
The cells were cultured for a further 36 h and were left
untreated, or were treated with 10 μM A23187 for 1 h. Cells
were lysed in 0.5 ml of ice-cold lysis buffer [50 mM Tris/HCl
(pH 7.2), 1 mM EGTA, 1 mM EDTA, 50 mM NaF, 1 mM sodium
pyrophosphate, 1% (w/v) Triton X-100, 0.1 mM PMSF, 1 mM
DTT (dithiothreitol), 0.1 mM benzamidine and 5 μg/ml soybean
trypsin inhibitor] after rapid rinsing in ice-cold PBS. The lysates
werecentrifuged(21000 gfor10 minat4◦C)andthesupernatants
frozen for later analysis.
Immunoprecipitation of AMPK and CaMKKβ
HEK-293 cell lysates (600 μg of protein) were incubated at 4◦C
for 2 h on a roller mixer with 5 μl of Protein G–Sepharose non-
covalently conjugated to 5 μgo fA M P K - α1/α2 or CaMKKβ
antibodies.Afterextensivewashing,theimmunoprecipitateswere
heated in SDS sample buffer, resolved by SDS/PAGE and blots
were probed with the antibodies indicated.
Immunoprecipitate kinase assays
Endogenous AMPK and the ARKs from HeLa cells were assayed
in immunoprecipitates as described in [24,30] using the AMARA
peptide [31] as a substrate. GST–AMPK-α1, GST–BRSK1 and
GST–BRSK2 were assayed as described previously [24]. For
CaMKKα/β, assays were performed with or without 1 μM
calmodulin and 1 mM CaCl2 as indicated in the text.
Estimation of the cellular ADP/ATP ratio
Culture medium was quickly aspirated from cells grown on
10 cm diameter culture dishes and cells were washed with 1 ml
of ice-cold PBS. After rapid aspiration of PBS, a minimal volume
of icecold 5% perchloric acid was added and the samples
vortex-mixed to ensure complete lysis. After centrifugation
(14000 g for 3 min at 4◦C) to remove acid-insoluble material, the
supernatant was extracted with two washes of an equal volume
of 1:1 tri-n-octylamine and 1,1,2-trichlorotriﬂuoroethane. The
nucleotides remaining in the aqueous phase were then separated
by capillary electrophoresis with on-column isotachophoretic
concentration, using run buffers consisting of 50 mM sodium
phosphateand50 mMNaCl(pH 5.2;leadingbuffer)and100 mM
Mes/Tris (pH 5.2; tailing buffer). To each buffer was added
0.2% hydroxyethylcellulose to decrease electro-osmotic ﬂow.
NucleotidepeaksweredetectedbyUVabsorbanceat260 nM,and
integrated using System Gold software (Beckman). Nucleotide
ratios were calculated from peak areas after correction for
retention times. Identiﬁcation of peaks as ATP, ADP and AMP
were conﬁrmed by additional runs spiked with internal standards
and analysis of absorbance spectra of individual peaks.
Statistics
Where multiple treatments were compared, one- or two-way
ANOVA was used as indicated, with Bonferroni’s post-hoc test
of selected treatments, using GraphPad Prism software.
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Figure 1 Alignment of activation loops of the ARKs and CaMKs
Sequences between the conserved DFG and YAAPE motifs were manually aligned, with gaps
indicatedbydots.Thearrowshowsthethreonineresidue(P)whosephosphorylationisrequired
for kinase activity. Residues identical between all sequences are boxed, while the conserved
hydrophobic residue at P−2 is in bold type.
Other analytical procedures
SDS/PAGEwasperformedusingprecastBisTris4–12%gradient
polyacrylamide gels in the Mops buffer system (Invitrogen).
Proteins were transferred on to nitrocellulose membranes (Bio-
Rad)usingtheXcellIIblotmodule(Invitrogen).Membraneswere
blocked for 1 h in TBS (Tris-buffered saline; 20 mm Tris/HCl
and 133 mM NaCl, pH 7.5) containing 5% (w/v) non-fat dried
skimmed milk. The membranes were probed with appropriate
antibody (0.1–1 μg/ml) in TBS-Tween 20 (0.1%)a n d2% (w/v)
non-fat dried skimmed milk. Detection was performed using
secondary antibody (1 μg/ml) coupled to IR 680 or IR 800
dye, and the membranes scanned using the Li-Cor Odyssey IR
imager. Protein concentrations were determined by Coomassie
Blue binding [32] with BSA as a standard.
RESULTS
Alignment of sequences around activation loop phosphorylation
sites
Figure1showsanalignmentoftheactivationloops(lyingbetween
the conserved DFG and APE motifs) of the ARKs, as well as the
four isoforms of CaMKI (CaMKI-α,- β,- δ and -γ) and the single
form of CaMKIV. All contain a threonine residue in the position
equivalent to Thr
172 in AMPK-α2, and a conserved hydrophobic
residue (usually leucine) two residues N-terminal to this. Many
of the other residues conserved between these sequences are also
found in other protein kinases not downstream of LKB1 and/or
CaMKKs, such as the DFG motif prior to the threonine, and
the CG and YAAPE motifs following it. Using a peptide library
approach, it has been shown that LKB1 only phosphorylates
threonine residues, and strongly prefers a leucine two residues
N-terminal to the threonine (i.e. at P−2) [33]. Figure 1 shows
that leucine is present at P−2i na l lA R K sa n di nC a M K 1 - α and
-β, although in CaMK1-δ, CaMKI-γ and CaMKIV, the residue at
P−2 is methionine. The features of primary sequence recognized
by CaMKKα and CaMKKβ, if any, are not known.
CaMKKs activate AMPK, but not ARKs, in HeLa cells
As an initial test of whether CaMKKs would activate any of
the ARKs we utilized HeLa cells, which express both CaMKKα
and CaMKKβ [13], but do not express LKB1 due to a biallelic
deletion of the gene in the cervical cancer from which the
cells were originally derived in 1951 [34]. We have shown
previously that the Ca
2+ ionophore A23187 caused activation of
endogenousAMPKinHeLacells,andthatthiseffectwasblocked
by the CaMKK inhibitor, STO-609 [13]. Activation of AMPK
(Figure 2A), and phosphorylation of Thr
172 (results not shown),
occurred in T-Rex
TM HeLa cells not only in response to A23187,
butalsoinresponsetostableexpressionofwild-typeactiveLKB1.
However, while stable expression of LKB1 in T-Rex
TM HeLa
cells increased the basal activity of the endogenous ARKs SIK1,
SIK2, SIK3, NUAK2, MARK1, MARK2/MARK3 and MARK4,
unlike AMPK none was signiﬁcantly activated by A23187 in the
parental cells (Figures 2B–2H) (for these experiments, MARK2
and MARK3 were assayed together because we do not have
an antibody that distinguishes between these two closely related
kinases [7]). These results show that the CaMKKs do not activate
any of the endogenous ARKs that are expressed in HeLa cells.
CaMKKβ is activated by Ca
2+ and calmodulin, but also has a
substantial basal activity [13]. We therefore examined the effect
of overexpressing CaMKKβ in HeLa cells in the absence of
aC a
2+ ionophore. Figure 3(A) shows that transient expression
of CaMKKβ in the parental T-Rex
TM HeLa cells caused almost
as much activation of AMPK as stable expression of LKB1 in
the same cell line, even without addition of A23187. Based on the
signal obtained in a Western blot using an anti-FLAG antibody
(both overexpressed proteins being FLAG-tagged), the expres-
sionofCaMKKβ intheseexperimentswassomewhathigherthan
that of LKB1 (Figure 3B). Despite the large activation of AMPK
by overexpression of CaMKKβ, none of the ARKs examined
(SIK1, SIK2, SIK3 or NUAK2) was activated compared with
the untransfected cells, although they were activated by stable
expression of LKB1 (Figures 3C–3F).
CaMKKβ activates the AMPK kinase domain, but not
BRSK1/BRSK2, in cell-free assays
The brain-speciﬁc ARKs, BRSK1 and BRSK2, are not expressed
in HeLa cells. In order to address whether they could be
phosphorylated and activated by CaMKKβ, we expressed their
combined kinase and UBA (ubiquitin-associated)-like domains
in bacteria as GST-fusion proteins, as well as the kinase domain
of the α1 isoform of the AMPK catalytic subunit (GST–α1-
KD). We also expressed GST–CaMKKβ in bacteria and a GST–
LKB1:FLAG-STRADα:myc–MO25α c o m p l e xi nH E K - 2 9 3
cells.Allfusionproteins/complexeswerepuriﬁedonglutathione–
Sepharoseandtheupstreamkinasesweretestedfortheirabilityto
phosphorylate and activate GST–α1-KD, GST–BRSK1 and GST-
BRSK2 in cell-free assays. Figure 4(A) shows that, although
the LKB1 complex and CaMKKβ were both able to activate
GST–α1-KD, only the LKB1 complex was able to activate GST–
BRSK1 and GST–BRSK2. There was also no phosphorylation
of BRSK1 or BRSK2 by CaMKKβ under conditions where there
was a robust phosphorylation of AMPK (results not shown).
These experiments were performed in the absence of Ca
2+
and calmodulin, since in cell-free assays CaMKKβ appears
to be at least partially independent of Ca
2+ and calmodulin
[13]. However, Figure 4(B) conﬁrms that BRSK1 was not
phosphorylated by CaMKKβ, even in the presence of Ca
2+ and
calmodulin.
Interestingly, although CaMKKβ was ineffective, CaMKKα
was able to activate (Figure 4C) and phosphorylate (Figure 4D)
GST–BRSK1 in the presence of Ca
2+ and calmodulin. However,
the concentration of CaMKKα used in these experiments was
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Figure 2 Effect of treatment of T-RexTM HeLa cells with A23187, or stable expression of LKB1 in the same cells, on the activity of endogenous AMPK and
ARKs
The indicated kinase was immunoprecipitated from cell lysates and assayed using the AMARA peptide as the substrate. Note that we do not have an antibody that distinguishes between MARK2
and MARK3 so the activity measured with this antibody could represent either MARK2 or MARK3, or a combination of the two. Values are means+ −S.D. for duplicate cell incubations. *P <0.05,
**P <0.01 and ***P <0.001, signiﬁcantly different from control without A23187 or LKB1.
approx. 20-fold higher than that required to obtain a comparable
level of phosphorylation of AMPK-α1 (results not shown).
AMPK and CaMKKβ do not form a stable complex
Anderson et al. [23] have recently reported evidence suggesting
that CaMKKβ can form a stable complex with the α and β
subunits of AMPK in the absence of a γ subunit. To test this
hypothesis, we initially studied whether overexpressed CaMKKβ
would co-precipitate with endogenous AMPK from extracts of
HEK-293 cells. Figure 5(A) shows that, although CaMKKβ
was readily detectable by Western blot analysis in the crude
cell lysates, none was detected by Western blot analysis in
immunoprecipitates made using anti-AMPK-α1/α2 antibodies
(although we could readily detect the α, β and γ subunits of
AMPK).Andersonetal.[23]claimedthattheinteractionbetween
CaMKKβ and AMPK was Ca
2+-dependent, but the same results
were obtained regardless of whether EDTA and EGTA were
present in the lysis and immunoprecipitation buffers. When the
converse experiment was performed, i.e. by immunoprecipitating
using an anti-CaMKKβ antibody, we could detect CaMKKβ,b u t
nottheα,β orγ subunitsofAMPKintheprecipitate,irrespective
of the presence of EDTA and EGTA in the buffers (Figure 5B).
Figure 5(C) shows results of expressing GFP-tagged α1 with
or without various combinations of β1, γ1 and FLAG-tagged
CaMKKβ in HeLa cells. It has been previously shown that co-
expression with β and γ subunits greatly increases expression
of GST-tagged α1 in COS7 cells, most likely because the
heterotrimericcomplexismorestableandisdegradedlessrapidly
[35]. Consistent with this, co-expression of GFP–α1 with β1a n d
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Figure 3 Effect of transient expression in T-RexTM HeLa cells of CaMKKβ, or stable expression of LKB1, on the phosphorylation and activity of AMPK and
ARKs
(A) Endogenous AMPK activity; (B) Western blot analysis of duplicate cell lysates shown in (A); (C–F) activities of endogenous SIK1, SIK2, SIK3 and NUAK2. Values are means+ −S.D. for duplicate
cell incubations. *P <0.05, **P <0.01 and ***P <0.001, signiﬁcantly different from control without CaMKKβ or LKB1.
γ1, but not β1 alone, led to a 3–4-fold increase in its expression;
co-expression with γ1 together with GFP–α1 also increased the
expression of β1. When CaMKKβ was expressed, the protein
was expressed at equal levels irrespective of whether or not
particularAMPKsubunitshadbeenco-expressed.If,assuggested
by Anderson et al. [23], CaMKKβ forms a complex with AMPK
α andβ subunitsintheabsenceofγ,onemighthaveexpectedthat
co-expression of CaMKKβ would have stabilized and increased
theexpressionofGFP–α1andβ1intheabsenceofγ1.Infact,the
opposite was observed: when GFP–α1a n dβ1 were co-expressed
with CaMKKβ, their expression level was reduced (compare
lane 7 with lane 3 in Figure 5C). Only when GFP–α1a n dβ1
were co-expressed with γ1 was there a marked increase in their
expression.
Increasing Ca2+ and AMP causes a synergistic activation of AMPK
in HeLa cells
Although it had been proposed that AMP promoted
phosphorylationofAMPKbyLKB1[5],previousstudiessuggest
that this may have been caused by trace contamination of the
kinase preparations used with protein phosphatase, and that
the effect of AMP on Thr
172 phosphorylation is entirely via
inhibition of dephosphorylation [10]. This raised the question as
to why drugs such as AICAR (5-amino-4-imidazolecarboxamide
riboside), which is converted into the AMP mimetic ZMP [36],
or phenformin, which increases cellular AMP [5], do not activate
AMPK in HeLa cells [5], even though CaMKKβ is expressed
and is capable of phosphorylating Thr
172 in those cells [13].
One explanation was that the activity of CaMKKβ in cells with
basal Ca
2+ is so low that the endogenous protein phosphatase
activity is sufﬁcient to cause net dephosphorylation of Thr
172,
eventhoughdephosphorylationisbeinginhibitedbyAMP.Totest
this idea, we incubated HeLa cells with increasing concentrations
of the Ca
2+ ionophore A23187 in the presence and absence
ofphenformin.Asfoundpreviously[5],intheabsenceofA23187,
phenformin did not give a signiﬁcant stimulation of AMPK
activity, phosphorylation of Thr
172 on the AMPK α subunits,
or phosphorylation of the AMPK site on ACC (acetyl-CoA
carboxylase). As expected [13], in the absence of phenformin,
concentrations of A23187 up to 10 μM increasingly stimulated
AMPKactivity(Figure6A),aswellasphosphorylationofAMPK
and ACC (Figure 6B). However, Figure 6 reveals the new result
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Figure 4 Phosphorylation and activation of GST–AMPK-α1 (kinase domain only), GST–BRSK1 or GST–BRSK2 (kinase domains plus UBA-like domains) by
CaMKKs
(A) Activity of GST–AMPK-α1, –BRSK1 or –BRSK2 after incubation in the presence of MgATP for 1 h with or without CaMKKβ (minus Ca2+/calmodulin), or LKB1:STRADα:MO25α.( B)T i m e
courseofphosphorylationofGST–BRSK1byCaMKKβ plusCa2+/calmodulin,orLKB1:STRADα:MO25α.(C)ActivityofAMPK-α1andBRSK1afterincubationinthepresenceofMgATPfor1 hwith
or without CaMKKα plus Ca2+/calmodulin, or LKB1:STRADα:MO25α.( D) Time course of phosphorylation of GST–BRSK1 in the experiment shown in (C). Values are means+ −S.D. for duplicate
cell incubations. ***P <0.001, signiﬁcantly different from control without CaMKKβ or LKB1.
that the presence of phenformin sensitized the cells to A23187.
Thus the presence of phenformin shifted the curve of AMPK
phosphorylation and activation against A23187 concentration
to the left. A stimulation of the activation of AMPK, and
the phosphorylation of AMPK and ACC by phenformin was
particularly evident at 3 μM A23187. These results show that,
under appropriate conditions, phenformin can activate AMPK
even in cells lacking LKB1.
We repeated the experiments using 3 μM A23187 in the
presence and absence of phenformin or 2-deoxyglucose, another
agentthatcandepletecellularATP,andmeasuredAMPKactivity,
phosphorylation of ACC and AMPK, and levels of cellular
nucleotides (Figure 7). The level of AMP in HeLa cells under
basal conditions was too low to measure accurately, although it
could be detected in cells treated with phenformin and A23187
(results not shown). We therefore used ADP/ATP as a surrogate
for AMP/ATP, since the latter is expected to vary as the square
of ADP/ATP [37]. Phenformin and 2-deoxyglucose did not cause
phosphorylation of ACC or AMPK, or activation of AMPK, in
HeLacellsthathadnotbeentreatedwithaCa
2+ ionophore,despite
the fact that 2-deoxyglucose produced a large rise in ADP/ATP
ratio (any small effect of phenformin on the ADP/ATP ratio was
notsigniﬁcant).However,incellstreatedwith3 μMA23187,both
phenformin and 2-deoxyglucose signiﬁcantly stimulated AMPK
activity, and increased phosphorylation of ACC and AMPK,
over and above the effect of A23187 alone, with the effect of
phenformin being larger than that of 2-deoxyglucose (Figures 7A
and 7B). The increase in ADP/ATP induced by 2-deoxyglucose
was not affected by A23187 but, surprisingly, a much larger
increase in ADP/ATP occurred in the presence of A23187 in
cellstreatedwithphenformin(Figure7C).Despitethecontrasting
effects of phenformin and 2-deoxyglucose on cellular ADP/ATP
ratios, the results in Figure 7 conﬁrm that, under appropriate
conditions, both agents are capable of activating AMPK, even in
cells completely lacking LKB1.
DISCUSSION
Despite the close similarity in the sequences surrounding Thr
172
on AMPK and the equivalent threonine residue on the ARKs
(Figure 1), it is clear that the latter are not phosphorylated
signiﬁcantly by CaMKKs either in intact cells (Figures 2 and 3)
or in cell-free assays (Figure 4). We have shown previously that
HeLa cells lack LKB1 but express both CaMKKα and CaMKKβ,
although it was only when CaMKKβ was knocked down using
siRNA (small interfering RNA) that the phosphorylation and
activation of AMPK in response to Ca
2+ ionophores was reduced
[13]. Thus it seems that neither CaMKKα nor CaMKKβ are
capable of activating any of the ARKs that are expressed in
HeLa cells, i.e. SIK1 (SIK), SIK2 (QIK), SIK3 (QSK), NUAK2
(SNARK) or any of the MARKs. Similarly, overexpression of
CaMKKβ caused activation of AMPK in HeLa cells, but failed
to activate any of the ARKs tested (Figure 3).
BRSK1 (SAD-B) and BRSK2 (SAD-A) are brain-speciﬁc
kinases that are not expressed in HeLa cells. Fujimoto et al.
[38] recently reported a search for proteins from rat brain
extracts that interacted with the kinase domain of CaMKKα,a n d
detected both the α1 subunit of AMPK and BRSK1 (SAD-B).
They also reported that BRSK1 could be phosphorylated (at
Thr
189, equivalent to Thr
172 on AMPK-α1) and activated by both
CaMKKα and CaMKKβ, although the rate of phosphorylation
was much lower with CaMKKβ than CaMKKα. The results in
Figure 4 conﬁrm that CaMKKα is capable of phosphorylating
and activating BRSK1 in cell-free assays. However, in
the present study neither BRSK1 nor BRSK2 was signiﬁcantly
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Figure 5 AMPK and CaMKKβ do not form a stable complex
(A)C a M K K β was overexpressed in HEK-293 cells; the top panels show Western blot analysis
of CaMKKβ and actin in the cell lysates, whereas the bottom panels show Western blot
analysis performed on immunoprecipitates made with control immunoglobulin or
anti-AMPK-α1/α2 antibodies in the presence and absence of EDTA plus EGTA. (B)A s( A),
except that Western blot analysis was performed on immunoprecipitates made with control
immunoglobulin or anti-CaMKKβ antibodies in the presence and absence of EDTA plus EGTA.
(C) HeLa cells were transfected with various combinations of plasmids encoding GFP-tagged
AMPK-α1, AMPK-β1, AMPK-γ1 or FLAG–CaMKKβ. Lysates were analysed by Western
blotting using antibodies against GFP, pan-β, γ1, FLAG or actin. The top panel shows one
representativeexperiment,whereasthebottompanelshowsquantiﬁcationoftheanti-GFPsignal
fromﬁveexperiments;theresultsaresigniﬁcantlydifferentfromtheexpressionlevelofGFP-α1
alone (***P <0.001).
Figure 6 In cells lacking LKB1, phenformin increases activation and
phosphorylation by the Ca2+ ionophore A23187
(A) HeLa cells were treated with increasing concentrations of A23187 in the presence and
absence of 10 mM phenformin. AMPK was immunoprecipitated and assayed at 200μMA M P .
Results are means+ −range for duplicate cell incubations. (B) Cell lysates treated as in (A)w e r e
analysedbyWesternblottingusingantibodiesagainstthephosphorylatedformofACC(pACC),
streptavidin to detect total ACC, phosphospeciﬁcantibodiesagainst the Thr172 site on AMPK-α
(pT172) and antibodies against total AMPK-α1/α2 (AMPK-α).
phosphorylated by CaMKKβ, although the concentration
used was sufﬁcient to fully activate AMPK. It should also
be pointed out that the concentration of CaMKKα used to
phosphorylate BRSK1 in Figure 4 was approx. 20-fold higher
thanthatrequiredtoobtainacomparablelevelofphosphorylation
of AMPK-α1 (results not shown). In addition, AMPK is itself
a relatively poor substrate for CaMKKα, with CaMKKα being
approx. 7-fold less active against AMPK than CaMKKβ when
the activities of the two CaMKKs were normalized using
phosphorylation of CaMKI [13]. Thus BRSK1 appears to be
a poor substrate for CaMKKα and an even poorer subtrate for
CaMKKβ, and we propose that LKB1 is the major upstream
kinase for BRSK1 and BRSK2 in vivo. In support of this are
results of Barnes et al. [39], who knocked-out LKB1 in pyramidal
neurons of the cerebral cortex by crossing mice harbouring a
conditional ‘ﬂoxed’ allele with mice expressing Cre recombinase
from the Emx1 promoter. This almost abolished phosphorylation
of BRSK2 (SAD-A) and BRSK1 (SAD-B) at the threonine
residues equivalent to Thr
172, while not affecting phosphorylation
of AMPK at Thr
172. This ﬁnding can be explained if CaMKKβ
(or CaMKKα) provides an alternative upstream pathway for
activation of AMPK, but not BRSK1 and BRSK2, in the cerebral
cortex. Also in agreement with our results, Bright et al. [40]
reported that neither BRSK1 nor BRSK2 was activated in CCL13
cells overexpressing CaMKKβ, while Uboha et al. [41] reported
that CaMKK partially puriﬁed from mouse cortex (isoform not
speciﬁed) failed to phosphorylate MARK2 in cell-free assays.
Given that the sequences around the threonine residue in
the activation loop are highly conserved between AMPK and
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Figure7 Phenforminand2-deoxyglucosecauseincreasedphosphorylation
and activation of AMPK in HeLa cells treated with low concentrations of Ca2+
ionophore
(A) HeLa cells were treated with or without 3μM A23187 in the presence and absence of
10mMphenforminor100μM2-deoxyglucose(2DG)for1 h.AMPKactivitywasdeterminedin
immunoprecipitates, and results are means+ −S.D. (n=3). (B) Samples from the experiment
in (A) were analysed in duplicate by Western blotting using antibodies as described in
Figure 6(C). (C) ADP/ATP ratios in an experiment identical with that shown in (A). Cells were
extracted with perchloric acid and acid-free extracts analysed by capillary electrophoresis.
ADP/ATP ratios were determined and results are expressed as means+ −S.D. (n=3).
***P <0.001, signiﬁcantly different from relevant control without phenformin or 2DG, as
measured by one-way ANOVA; †††P <0.001, signiﬁcantly different from control without
A23187, as measured by one-way ANOVA.
the ARKs, it remains unclear why the latter should be
phosphorylated and activated by LKB1 complexes, but not by
CaMKK-α or -β. Our ﬁndings suggest that some feature of
the structure of the ARKs, other than the primary sequence
of the activation loop, may be required to determine this
speciﬁcity. This is supported by previous studies showing that
a peptide derived from CaMKIV was a very poor substrate
for CaMKKα compared with CaMKIV itself [42], and that
thermal denaturation of CaMKI or CaMKIV abolished their
phosphorylation by CaMKKα [42,43]. Thus the CaMKKs appear
to recognize determinants on CaMKI and CaMKIV other than
just the primary sequence of the activation loop.
Our ﬁndings have important implications regarding the
regulation of the ARKs. None of them appears to be interacting
with the regulatory β or γ subunits of the AMPK complex
[44] and, consistent with this, those that are expressed in
skeletal muscle (SIK2, SIK3, MARK2/3 and MARK4) are not
phosphorylated or activated when AMPK is activated in muscle
by contraction, AICAR or phenformin [8]. The results of the
present study show that the ARKs, unlike AMPK itself, are
not regulated by increases in cytosolic Ca
2+ via activation of
CaMKK. That being the case, what are the upstream signals
that regulate the ARKs? In most cases this remains unclear,
although there is some information available in the case of SIK1.
SIK1 was discovered as a protein kinase induced in the adrenal
glands of rats fed a high-salt diet [45], and is also induced at
the transcriptional level by glucagon and forskolin in primary rat
hepatocytes[46].InY1mouseadrenocorticaltumourcellstreated
with adrenocorticotrophic hormone, SIK1 is phosphorylated at
a C-terminal site by PKA (protein kinase A), resulting in its
translocation to the cytoplasm [47]. Thus SIK1 may be regulated
by altered transcription and/or by altered subcellular localization
rather than by altered phosphorylation by LKB1.
Anderson et al. [23] recently provided evidence suggesting
that CaMKKβ (also known as CaMKK2) can form a stable
complex with the AMPK α and β subunits. They expressed
FLAG-tagged CaMKKβ in HEK-293 cells and, using anti-FLAG
antibodies, showed co-precipitation not only of calmodulin, but
also of AMPK α subunits and ACC, the latter two detected using
phosphospeciﬁc antibodies against Thr
172 (AMPK) and Ser
79
(ACC). These co-precipitation events appeared to be dependent
on Ca
2+ because they were not observed in the presence of EDTA
and EGTA. Anderson et al. [23] also detected in the anti-FLAG
immunoprecipitatestheα1,α2,β1andβ2subunitsofAMPK,but
not γ1, although they could detect the latter in cell extracts. They
therefore proposed that CaMKKβ could replace the γ subunit
within the AMPK complex. The results of the present study do
not support this concept. When CaMKKβ was overexpressed
in HEK-293 cells, we could not detect any AMPK-α,- β or -γ
subunits in an immunoprecipitate made using anti-CaMKKβ
antibodies, either with or without EDTA and EGTA in the lysis
and immunoprecipitation buffers (Figure 5B). In the converse
experiment (which was not reported by Anderson et al. [23])
we found that no CaMKKβ was detected in an anti-AMPK-
α1/α2 immunoprecipitate, although we could readily detect the
α, β and γ subunits of AMPK (Figure 5A). This suggests to us
that the AMPK subunits recovered by Anderson et al. [23] in
their anti-FLAG immunoprecipitates may have been an artefact
caused by the high level of FLAG–CaMKKβ expression in the
cells.
Wealsoaddressedthesamequestioninadifferentway,making
useofpreviousﬁndingsthattheα subunitsofAMPKareunstable
unlessco-expressedwithβ andγ subunits[35].Thisphenomenon
can be explained by recent structural studies showing that the C-
terminal region of the β subunit forms extensive interactions with
the C-terminal domain of α and with the N-terminal region of γ
[4]. If these subunits do not ﬁnd their interaction partners, they
may be recognized as misfolded proteins and become degraded.
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Wearguedthat,iftheAMPKα andβ subunitscanformacomplex
with CaMKKβ in the absence of the γ subunit, then co-expres-
sion with CaMKKβ should stabilize the α subunit in the presence
of a β subunit. However, Figure 5(C) shows that this is not the
case:inthepresenceofβ1theγ1subunitstabilizestheα1subunit,
but CaMKKβ does not substitute for γ1 in this respect. Rather
than stabilizing the AMPK α and β subunits, overexpression of
CaMKKβ decreased the level of expression of all three AMPK
subunits (Figure 5C), perhaps because the transfected DNA was
competing for the available biosynthetic machinery.
Finally, the results shown in Figures 6 and 7 show that the
two known mechanisms by which phosphorylation of AMPK
is activated, i.e. inhibition of dephosphorylation by AMP and
increased phosphorylation via activation of CaMKKβ by Ca
2+
can, under the right circumstances, be synergistic. They also
provide an explanation for our previous ﬁndings [5] that agents
that cause increases in AMP (e.g. phenformin) or that are
converted into an AMP mimetic (AICAR) do not increase
phosphorylation and activation of AMPK in HeLa cells. The
basal rate of phosphorylation of Thr
172 in these cells, which lack
LKB1 and would only have the Ca
2+-independent activity of
CaMKKβ, appears to be too low for any effect of increased AMP
on dephosphorylation to become evident. However, if CaMKKβ
is activated using the Ca
2+ ionophore A23187 at sub-optimal
concentration (3 μM), the effect of a rise in AMP to inhibit
dephosphorylation now becomes apparent (Figures 6 and 7). In
agreement with our ﬁndings, Yu et al. [48] have recently reported
that A23187 and AICAR act in an additive manner to inhibit cell
proliferation and/or survival in HeLa cells.
A somewhat unexpected ﬁnding shown in Figure 7 was
that, although treatment with 3 μM A23187 alone did not
signiﬁcantly increase the ADP/ATP ratio, when combined with
10 mM phenformin it caused a much larger increase in this ratio
than that caused by phenformin alone. By contrast, 2-deoxy-
glucosetreatmentincreasedADP/ATP,buttherewasnoadditional
effect when it was added together with A23187. Phenformin is
an inhibitor of complex I of the respiratory chain [49,50], thus
potentially causing inhibition of mitochondrial ATP synthesis,
whereas A23187 is a Ca
2+ ionophore that causes release of
cytosolic Ca
2+, potentially increasing ATP turnover due to
activation of Ca
2+ pumps. Although 2-deoxyglucose is often
described as an inhibitor of glycolysis, its major effect may be to
accelerateATPconsumption,becauseitisrapidlyphosphorylated
within the cell to 2-deoxyglucose 6-phosphate. We propose that
a combination of treatments that both inhibit ATP synthesis and
accelerateATPturnover(phenforminandA23187),asopposedto
two different treatments that accelerate ATP turnover (2-deoxy-
glucose and A23187) may make it more difﬁcult for the cells to
maintain their energy status. The very large increase in AMPK
activity in response to addition of both A23187 and phenformin
(Figure 7A) could be explained by an increase in cytosolic Ca
2+
coupled with a larger increase in AMP than that caused by
2-deoxyglucose. Whatever the explanation, the results in Figure 7
show that treatments which elevate cellular AMP (phenformin
and 2-deoxyglucose) can, under the right circumstances (elevated
cytosolic Ca
2+), cause increased phosphorylation and activation
of AMPK even in cells lacking LKB1. Thus the effect of AMP on
phosphorylation of AMPK is independent of the upstream kinase
utilized.
Increased cytosolic Ca
2+ tends to switch on many processes
that consume ATP, such as operation of ion pumps or channels,
interaction of motor proteins, and membrane trafﬁcking and
secretion. The ability of Ca
2+ and AMP to additively activate
AMPK to restore cellular energy balance may therefore have
physiological relevance.
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